INS and type 2 diabetes mellitus: In SURPASS-3, Tirzepatide was superior to titrated insulin Degludec with greater reductions in HbA1c as well as body weight observed at week 52 in insulin-naïve T2DM patients treated with metformin alone or in combination with an SGLT2 inhibitor [45].